INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Cell And Gene Therapy Commercialization Handbook

  Bringing advanced therapeutics to market requires overcoming hurdles in regulation, logistics, and reimbursement. Learn how to coordinate supply chains and implement adaptive strategies for long-term commercial success.

• Unlock The Future Of Market Access In 2026: A Guide To Navigating A Shifting Healthcare Landscape

  Navigating the future healthcare landscape requires early strategic planning and organizational agility to manage policy shifts. From AI implementation to global pricing dynamics, understanding these trends is essential for ensuring timely patient access.

• Notes From A VC: What It Takes To Be Impactful In Longevity Science

  Impact in longevity science (particularly for cell and gene therapies) is not about chasing the next unicorn; it is about carrying transformative ideas across the threshold of scientific validation, regulatory trust, and societal acceptance.

• Advancing Hematology and Cell Therapy Innovation with AstraZeneca's Aliya Omer

  On episode 115 of Cell & Gene: The Podcast, Host Erin Harris talks to Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca, who shares valuable insights from her rich experience leading cell therapy development across multiple top companies.

• Tips For Partnering With Health Systems: A Critical Step For CGT Commercialization

  Collaborating with health systems is key to CGT commercialization. Learn how to address operational and financial challenges to ensure processes are scalable and patient access is streamlined.

• Commercializing Your First CGT Product: Value Chain Planning

  Effective value chain planning for cell and gene therapies requires early decisions on manufacturing, complex cold storage solutions, flexible reimbursement models, and scalable partnerships.

• Future Proof Process Design Through Risk-Focused Decisions, Automation Readiness, And Regulatory Pragmatism

  In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene share that future proofing begins with deep process understanding.

• The Moral Economics Of Precision Medicine

  The most complex and expensive drugs to develop often target terrible diseases that affect only a small number of people and will never reach blockbuster status.

• Understanding CLL And SLL Treatment Evolution

  Tevogen Bio's Dr. Neal Flomenberg and Dr. Dolores Grosso discuss the shift from chemotherapy to targeted therapies such as Jaypirca and highlight Tevogen’s antigen-specific T cell platform as a new frontier in cancer and infectious disease treatment.

• Know Your Product, Know Your Path: A Primer On Advanced Therapy Development

  To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.